TRMT1

Across TCGA pan-cancer cohorts, TRMT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRMT1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRMT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRMT1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where TRMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.479	0.852	<.001	64	view →
LSCC	DFS	Tertile	II,III,IV	0.927	0.432	<.001	36	view →
LUAD	DFS	Median	III,IV	0.722	0.246	.004	22	view →
PDAC	OS	Tertile	IV	0.973	0.443	.024	12	view →
GBM	OS	Median	All	0.627	0.438	.007	11	view →
CCRCC	OS	Quartile	All	0.794	1.000	.004	10	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRMT1–HNSC (DFS)

Open the HNSC breakdown →